Brussels, 6 May 2025
The European Commission has approved, under the EU Merger Regulation, the acquisition of joint control of Bluebird Bio Inc by SK Capital Partners L.P. and the Carlyle Group (‘Carlyle’), all of the US.
The transaction relates primarily to the pharmaceutical sector, with a focus on gene therapies.
The Commission concluded that the notified transaction would not raise competition concerns, given the limited impact on the European Economic Area and that the companies are not active in the same or vertically related markets. The notified transaction was examined under the simplified merger review procedure.
More information is available on the Commission’s competition website, in the public case register under the case number M.11935.